Are There Peptide Protocols for Perimenopausal Women?

Perimenopause does not begin with estrogen dropping. That is the common assumption, and it is wrong in a way that matters for every decision you make after it.

Here is what is actually happening. Your reproductive system runs on a monthly cycle where your ovaries release an egg, and after that egg is released, the follicle it came from transforms into something called the corpus luteum, which is a temporary gland that produces progesterone for the second half of your cycle. When perimenopause begins, your ovaries start skipping ovulations. No ovulation means no corpus luteum, and no corpus luteum means no progesterone. So progesterone falls first, often years before anything dramatic happens to estrogen.

Estrogen tells a different story. Research published in the Journal of Clinical Endocrinology and Metabolism by Santoro and colleagues in 2004 showed that estrogen during perimenopause does not steadily decline the way most people picture it. It spikes. It crashes. It spikes again. Estrogen levels in perimenopausal women were actually found to be higher on average than in younger women during parts of the cycle, and then they would plummet unpredictably. The problem is not that estrogen is too low. The problem is that the ratio between progesterone and estrogen has broken down, because the progesterone that used to balance estrogen is gone.

That ratio is why the symptoms feel so chaotic. Sleep falls apart because progesterone has a calming, sleep-promoting effect on the brain through its conversion to a compound called allopregnanolone, which acts on the same receptors as anti-anxiety medications. Visceral fat accumulates around the midsection because estrogen unopposed by progesterone shifts where and how the body stores fat. Anxiety increases for the same neurological reason the sleep worsens. And body composition deteriorates even when diet and training have not changed, because the hormonal environment driving muscle retention and fat distribution has shifted underneath everything else.

So when someone comes in asking about peptide protocols for perimenopause, the first thing that has to be clear is that peptides are not the first layer. They are the second layer. You do not skip to the second layer before you have handled what is actually driving the problem.

The appropriate first move is progesterone replacement, not estrogen. The reason you do not start with estrogen is that your ovaries are still producing it, just unpredictably, so adding exogenous estrogen on top of an ovary that still spikes on its own can make the hormonal environment more erratic, not less. A 2014 review by Prior in Facts, Views and Vision in ObGyn laid out the case for progesterone as first-line therapy specifically in perimenopause for exactly this reason. And a Phase III randomized controlled trial published in Scientific Reports in 2023 by Prior and colleagues showed that oral micronized progesterone improved sleep quality and reduced night sweats compared to placebo, which is direct evidence that this intervention moves the outcome variables most women are trying to fix.

To know where you are in that process, your doctor can measure something called anti-Mullerian hormone, which is a marker produced by follicles in your ovaries that reflects how much ovarian reserve you have remaining. A 14-year study of 401 women published in 2012 by Freeman and colleagues showed that AMH levels predict menopause timing with real precision. When AMH becomes essentially undetectable and you have gone 12 consecutive months without a period, that is the definition of menopause, and that is when adding estrogen makes clinical sense because the unpredictable ovarian output that complicated things during perimenopause is now gone.

That transition point also matters for one of the reasons peptides underperform before it.

The growth hormone axis is one of the three systems where peptides can meaningfully help during this time. Peptides called secretagogues, like tesamorelin or CJC-1295, work by signaling the pituitary gland to release more growth hormone, which then drives production of IGF-1, the downstream factor that supports lean mass and metabolic function. The problem is that this pituitary response depends on estrogen being present. Research published in the Journal of Clinical Endocrinology and Metabolism by Shah and colleagues in 2019 measured pulsatile growth hormone secretion in women with and without estradiol and found the difference was statistically significant at P equals 0.001, meaning the pituitary's response to growth hormone signaling is substantially blunted when estrogen is absent or unstable. Estrogen potentiates the pituitary's response to GHRH, which is the signal those secretagogues are trying to amplify. If estrogen is erratic, the signal lands on a less responsive receiver.

This is why stabilizing the hormonal foundation first is not just philosophically correct. It is mechanistically what allows the peptides to work.

The second system where peptides can help is sleep and anxiety, and these two are connected because the same neurological disruption that impairs sleep in perimenopause also drives the anxiety that makes sleep harder to initiate. Peptides like Selank work on the anxiety side of that equation. DSIP, or delta sleep-inducing peptide, has been studied in the context of sleep architecture, though the evidence base here is thinner and more theoretical than what exists for the secretagogues or the GLP-1 class. These are supportive tools, not solutions.

The third system is metabolic control, and this is where the GLP-1 and dual-agonist class of peptides like tirzepatide or retatrutide become relevant. The visceral fat accumulation that comes with the progesterone-to-estrogen imbalance is driven by real hormonal mechanisms, and while fixing the hormone imbalance addresses the cause, the weight itself has downstream effects on insulin sensitivity and inflammation that can compound the problem. Targeting food intake and appetite regulation through the GLP-1 axis is a legitimate lever while the hormonal environment is being stabilized.

The full picture is this: perimenopause is driven by a progesterone deficiency that creates an estrogen dominance relative to what should be there, and that ratio disrupts sleep, body composition, anxiety, and metabolic function all at once. Peptides can assist with all three of those downstream effects, but they are working against a current that hormonal therapy is designed to stop. An estrogen-depleted or hormonally unstable pituitary does not respond to secretagogues the way a hormonally stable one does. A body that is fighting visceral fat accumulation driven by unopposed estrogen is harder to pull back through appetite suppression alone.

The peptides are not wrong for this situation. They are just operating one layer above where the actual problem lives.

---

References

1. Santoro et al., 2004, Journal of Clinical Endocrinology & Metabolism — progesterone declines before estrogen, estrogen becomes erratic during perimenopause
2. Freeman et al., 2012, Journal of Clinical Endocrinology & Metabolism — AMH predicts menopause timing (Penn Ovarian Aging Study, 401 women, 14 years)
3. Prior, 2014, Facts, Views & Vision in ObGyn — progesterone as appropriate first-line therapy for perimenopause
4. Shah et al., 2019, Journal of Clinical Endocrinology & Metabolism — pulsatile GH secretion significantly blunted without estradiol (P = 0.001), estrogen potentiates pituitary GHRH response
5. Prior et al., 2023, Scientific Reports — Phase III RCT, oral micronized progesterone improved sleep quality and reduced night sweats vs placebo

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness